![eyenovia-logo 3 eyenovia-logo 3](/sites/g/files/knoqqb31001/themes/site/nir_pid2702/client/images/eyenovia-logo-3.png)
Investor Relations
Investor Relations
Corporate Profile
Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.
Price |
Change |
Volume |
Data Provided by Refinitiv. Minimum 15 minutes delayed.